Núñez Jorge H, Moreira Felipe, Escudero-Cisneros Berta, Martínez-Peña Judith, Bosch-García David, Anglès Francesc, Guerra-Farfán Ernesto
Servicio de Traumatología y Cirugía Ortopédica, Hospital Universitario de Mutua Terrassa, Terrassa, Barcelona, España; Artro-Esport, Centro Médico Teknon, Terrassa, Barcelona, España.
Artro-Esport, Centro Médico Teknon, Terrassa, Barcelona, España.
Rev Esp Cir Ortop Traumatol. 2024 Jul-Aug;68(4):409-421. doi: 10.1016/j.recot.2023.07.003. Epub 2023 Aug 6.
The aim of this study was to evaluate the efficacy of aspirin versus low molecular weight heparins (LMWH) for the prophylaxis of venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing total knee arthroplasty (TKA) and/or total hip arthroplasty (THA).
Systematic review and meta-analysis. Sixteen studies were selected. The risk of VTE, DVT and PE were analyzed. Mortality, risk of bleeding and surgical wound complications was also analyzed.
248,461 patients were included. 176,406 patients with thromboprophylaxis with LMWH and 72,055 patients with aspirin thromboprophylaxis. There were no significant differences in the risk of VTE (OR = 0.93; 95% CI: 0.69-1.26; P = .64), DVT (OR = 0.72; 95% CI: 0.43-1.20; P = .21) or PE (OR = 1.13; 95% CI: 0.86-1.49; P = .38) between both groups. No significant differences were found in mortality (P = .30), bleeding (P = .22), or complications in the surgical wound (P = .85) between both groups. These same findings were found in the sub-analysis of only randomized clinical trials (P>.05).
No increased risk of PE, DVT, or VTE was found among patients with aspirin thromboprophylaxis versus patients with LMWH thromboprophylaxis. There was also no greater mortality, greater bleeding, or greater complications in the surgical wound found among patients with aspirin thromboprophylaxis versus patients with LMWH thromboprophylaxis.
本研究旨在评估阿司匹林与低分子量肝素(LMWH)在全膝关节置换术(TKA)和/或全髋关节置换术(THA)患者中预防静脉血栓栓塞(VTE)、深静脉血栓形成(DVT)和肺栓塞(PE)的疗效。
系统评价和荟萃分析。选取了16项研究。分析了VTE、DVT和PE的风险。还分析了死亡率、出血风险和手术伤口并发症。
纳入248,461例患者。176,406例患者接受LMWH血栓预防,72,055例患者接受阿司匹林血栓预防。两组在VTE风险(OR = 0.93;95%CI:0.69 - 1.26;P = 0.64)、DVT风险(OR = 0.72;95%CI:0.43 - 1.20;P = 0.21)或PE风险(OR = 1.13;95%CI:0.86 - 1.49;P = 0.38)方面无显著差异。两组在死亡率(P = 0.30)、出血(P = 0.22)或手术伤口并发症(P = 0.85)方面也无显著差异。在仅对随机临床试验的亚组分析中也发现了相同的结果(P>0.05)。
与接受LMWH血栓预防的患者相比,接受阿司匹林血栓预防的患者中未发现PE、DVT或VTE风险增加。与接受LMWH血栓预防的患者相比,接受阿司匹林血栓预防的患者中也未发现更高的死亡率、更多的出血或更多的手术伤口并发症。